Cardiac safety of fingolimod 0.5 mg during the first-dose observation in a 4-month, open-label, multicentre FIRST study in relapsing multiple sclerosis patients - Gold, R; Kappos, L; Palace, J; Siever, A; Marrosu, M; Gottschalk, R; Bijarnia, M; Keil, A; Tomic, D; von Rosenstiel, P; Comi, G (2012)